| MINK THERAPEUTICS |
| USA |
| Gesundheit |
| US6036932019 / A40ZAV |
| 6Q40 (Frankfurt) / INKT (NASDAQ) |
| FRA:6Q40, ETR:6Q40, 6Q40:GR, NASDAQ:INKT |
| - |
| https://minktherapeutics... |
|
MiNK Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies for cancer and other immune-mediated diseases. Its platf..
>Volltext.. |
| 46.86 Mio. EUR |
| 39.88 Mio. EUR |
| - |
| -10.51 Mio. EUR |
| -10.67 Mio. EUR |
| -2.53 EUR |
| 4.42 Mio. EUR |
| 11.41 Mio. EUR |
| - |
| 1.03 |
| - |
| -15.84% |
| - |
| - |
| - |
| - |
| MINK THERAPEUTICS, MINK THERAPEUTIC |
| 15.05.26 |
|
||||
|
||||
|
||||
|
||||
|